LuciLazer

LuciLazer uses and dosage

LuciLazer (Lazertinib), generic Lazcluze is a prescription medicine used to treat bispecific antibody targeting EGFR and MET, this combination has been approved for the first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR Exon 19 deletions or Exon 21 L858R substitution mutations. This regimen aims to provide a chemotherapy-free alternative to traditional treatments. LuciLazer manufactured by Lucius Pharma Ltd. in Laos. Lazertinib orally once daily with or without food.

LuciLazer side effects

The most common adverse reactions are: Rash, Itching, Infected skin around your nail, Mouth sores, Muscle or joint pain, Fluid retention, Numbness, tingling, or burning in your arms, feet, or face, Tiredness, Diarrhea, constipation, or nausea, Decreased appetite, COVID-19 infection, Bleeding, Blood clots (see below), Eye problems (see below).

Originator brand

Lazcluze (by Janssen)

Made by

Lucius Pharma

This information is provided for reference only and is not medical advice. Always consult a qualified healthcare professional.